Trial Profile
A Multi-Center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glibenclamide (Primary) ; Glibenclamide (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms GAMES-PILOT
- Sponsors Remedy Pharmaceuticals
- 31 Oct 2014 New trial record